Clinical Trial

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Name: A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) — clinical trial record (NCT07622186)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Trial Details

NCT Number	NCT07622186
Lead Sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions	Non-Small Cell Lung Cancer
Enrollment	150 participants
Start Date	2026-07-31
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-03